Trial Profile
A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary) ; Gemcitabine
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- Acronyms VANGOGH
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 Aug 2012 Planned end date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 13 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.